Thursday - May 15, 2025

LOGIN  |  REGISTER
Astria Therapeutics
Viking Therapeutics

Waystar CEO to Speak at Canaccord Genuity Growth Conference

August 09, 2024 | Last Trade: US$39.50 0.39 1.00

LEHI, Utah and LOUISVILLE, Ky., Aug. 9, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at the Canaccord Genuity Growth Conference on Tuesday, August 13, 2024, at 10:00 a.m. ET.

The presentation will be viewable live on Waystar's Investor Relations website at https://investors.waystar.com/news-events/events. A recording will be available on the site afterward.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Investor Contact
Sandy Draper
investors@waystar.com
502-238-9511

Media Contact
Kristin Lee
kristin.lee@waystar.com 

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page